Traws Pharma, Inc.
For the period ended May 15, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 15, 2026 · Filed May 15, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Hantavirus Program:
Hantavirus Program:
Intended Indication and Market Potential: Hantavirus, a rodent-borne negative-strand RNA virus that typically results in a 30-50% fatality rate when transmitted to humans and which has been implicated as the cause of several cruise ship fatalities and serious illnesses in recent days 1.
**Next Steps:**Traws plans to move rapidly to advance a clinical candidate for hantavirus treatment.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.